Building its antibody-drug conjugate portfolio, Seattle Genetics has agreed to in-license a family of monoclonal antibodies directed to a single target from Five Prime Therapeutics in exchange for US$5 M upfront. The target of the deal has not been disclosed. Interestingly, the deal follows a series of setbacks for Five Prime including multiple job cuts, corporate restructuring and a recent Phase II trial failure for cabiralizumab which is partnered with Bristol-Myers Squibb.